BioSculpture Technology, Inc. (“BST”) is a commercial stage medical device manufacturer developing a patented and prototyped minimally invasive device for the endoscopic removal of visceral or “belly” fat as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. We believe our method and device will save lives, improve life outcomes, and significantly reduce healthcare costs.
The Burgeoning Obesity Problem
2/3 of the population is overweight and 43% is forecast to be obese in a few years. US Health reports there are 2.1 Billion people suffering from obesity about the globe and obesity costs exceed $2 Trillion USD. 80% of these obese people will develop type 2 diabetes mellitus which is the leading cause of renal failure needing dialysis and a frequent cause of blindness. Obesity doesn’t just shorten your life, but it lessens the quality of it.
Obesity surgery expenditures exceeded $1.9 Billion in 2014. Marketsandmarkets.com forecasts the obesity market to reach $17 trillion USD by 2030. There is an enormous unmet need in developed countries and a large potential in lower income countries due to the cost-effective nature of the device for a minimally invasive treatment of obesity which is safer and highly effective.
World’s First Direct Removal of the Belly Fat Which Kills You
Visceral or “belly” fat not only causes sleep apnea and gastric reflux but secretes the cellular hormones which are responsible for all the complications of obesity – diabetes, hypertension, vascular disease, strokes, heart attacks, autoimmune diseases, and cancers. Patented and proprietary methods and devices have been prototyped and are being tested. We believe our device is distinct from and superior to all current or experimental therapies because there is no need to cut into the stomach or bowel, rearrange the alimentary tract, leave behind a foreign body, or be limited by a weight loss plateau. We have been granted three (3) U.S. patents on both method and the device and an E.P.O application and numerous other patents are pending. Following the successful completion of the current equity offering, we expect our device to become commercially available for “tissue and fluid aspiration, including body sculpting and liposuction” under a 510(k) and subsequently be promoted as a treatment of obesity after clinical trials and regulatory approvals.